Advertisement

Topics

Pfizer’s EPO Biosimilar Stalls In US On Hospira Compliance Woes

12:01 EDT 22 Jun 2017 | SCRIP

US FDA hands Pfizer its second complete response letter for its proposed biosimilar to Epogen/Procrit, citing manufacturing compliance concerns at...

      

Related Stories

 

Original Article: Pfizer’s EPO Biosimilar Stalls In US On Hospira Compliance Woes

NEXT ARTICLE

More From BioPortfolio on "Pfizer’s EPO Biosimilar Stalls In US On Hospira Compliance Woes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...